Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


10.06.2019

1 Acta Cytol
2 AJR Am J Roentgenol
1 Am J Clin Oncol
1 Am J Clin Pathol
1 Ann Oncol
1 Ann Surg Oncol
3 BMC Cancer
3 Breast Cancer
14 Breast Cancer Res Treat
9 Breast J
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
1 Eur J Cancer
4 Int J Cancer
2 Int J Oncol
2 J Biol Chem
1 J Clin Invest
5 J Clin Oncol
2 J Natl Cancer Inst
1 J Surg Oncol
1 JAMA
2 Lancet Oncol
3 N Engl J Med
1 Oncogene
3 Oncol Rep
1 Oncology
4 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Cytol

  1. AGARWAL C, Chauhan V, Pujani M, Singh K, et al
    Masood's and Modified Masood's Scoring Index: An Evaluation of Fine Needle Aspiration Cytology of Breast Lesions with Histopathological Correlation.
    Acta Cytol. 2019;63:233-239.
    PubMed     Text format     Abstract available


    AJR Am J Roentgenol

  2. GREENWOOD HI, Wong JM, Mukhtar RA, Alvarado MD, et al
    Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    AJR Am J Roentgenol. 2019 Jun 5:1-5. doi: 10.2214/AJR.19.21378.
    PubMed     Text format     Abstract available

  3. HUNT KN, Conners AL, Goetz MP, O'Connor MK, et al
    Comparison of (99m)Tc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy.
    AJR Am J Roentgenol. 2019 Jun 5:1-12. doi: 10.2214/AJR.18.20628.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  4. LEONE JP, Leone J, Zwenger AO, Vallejo CT, et al
    Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
    Am J Clin Oncol. 2019 Jun 3. doi: 10.1097/COC.0000000000000563.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  5. LIN L, Sirohi D, Coleman JF, Gulbahce HE, et al
    American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory.
    Am J Clin Pathol. 2019 Jun 7. pii: 5512208. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Oncol

  6. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 4. pii: 5499075. doi: 10.1093.
    PubMed     Text format    


    Ann Surg Oncol

  7. WANG MM, Joseph KA
    ASO Author Reflections: Improving the Rate of Breast Reconstruction in Underserved Populations.
    Ann Surg Oncol. 2019;26:827-828.
    PubMed     Text format    


    BMC Cancer

  8. YANG Y, Wang Y, Deng H, Tan C, et al
    Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
    BMC Cancer. 2019;19:541.
    PubMed     Text format     Abstract available

  9. CHANG VC, Cotterchio M, Khoo E
    Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:543.
    PubMed     Text format     Abstract available

  10. OGITA M, Sekiguchi K, Akahane K, Ito R, et al
    Damage to sebaceous gland and the efficacy of moisturizer after whole breast radiotherapy: a randomized controlled trial.
    BMC Cancer. 2019;19:125.
    PubMed     Text format     Abstract available


    Breast Cancer

  11. BEYAN C, Beyan E
    Mean platelet volume may not be an independent prognostic factor in breast cancer patients with type 2 diabetes mellitus.
    Breast Cancer. 2019 Jun 3. pii: 10.1007/s12282-019-00983.
    PubMed     Text format    

  12. MASUDA N, Mukai H, Inoue K, Rai Y, et al
    Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
    Breast Cancer. 2019 Jun 5. pii: 10.1007/s12282-019-00984.
    PubMed     Text format     Abstract available

  13. CHENG X, Tan S, Duan F, Yuan Q, et al
    Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM.
    Breast Cancer. 2019 Jun 6. pii: 10.1007/s12282-019-00980.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  14. JOZSA F, Ahmed M, Baker R, Douek M, et al
    Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?
    Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05299.
    PubMed     Text format     Abstract available

  15. RUIZ-BORREGO M, Guerrero-Zotano A, Bermejo B, Ramos M, et al
    Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
    Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05296.
    PubMed     Text format     Abstract available

  16. ELFGEN C, Varga Z, Reeve K, Moskovszky L, et al
    The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05298.
    PubMed     Text format     Abstract available

  17. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05292.
    PubMed     Text format     Abstract available

  18. MURPHY JD, Sandler D, White AJ, O'Brien KM, et al
    Severe acne and risk of breast cancer.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05302.
    PubMed     Text format     Abstract available

  19. TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
    Correction to: Racial disparities in surveillance mammography among older breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05291.
    PubMed     Text format     Abstract available

  20. JERUSALEM G, Lancellotti P, Kim SB
    HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05303.
    PubMed     Text format     Abstract available

  21. LAO C, Lawrenson R, Edwards M, Campbell I, et al
    Treatment and survival of Asian women diagnosed with breast cancer in New Zealand.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05310.
    PubMed     Text format     Abstract available

  22. MELISKO ME, Assefa M, Hwang J, DeLuca A, et al
    Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05309.
    PubMed     Text format     Abstract available

  23. BHANDARI S, Ngo P, Kute B, Mandadi M, et al
    Adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging: a pilot study.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05308.
    PubMed     Text format     Abstract available

  24. DIERAS V, Bonnefoi H, Alba E, Awada A, et al
    Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05305.
    PubMed     Text format     Abstract available

  25. PLASTERER C, Tsaih SW, Peck AR, Chervoneva I, et al
    Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.
    Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05307.
    PubMed     Text format     Abstract available

  26. MCCLELLAND S 3RD, Rhome RM, Zellars RC
    Radiation oncology crossword: breast cancer.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05304.
    PubMed     Text format    

  27. WOLFF JL, Aufill J, Echavarria D, Heughan JA, et al
    Sharing in care: engaging care partners in the care and communication of breast cancer patients.
    Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05306.
    PubMed     Text format     Abstract available


    Breast J

  28. KUDELA E, Nachajova M, Danko J
    Is the HPV virus responsible for the development of breast cancer?
    Breast J. 2019 Jun 6. doi: 10.1111/tbj.13399.
    PubMed     Text format    

  29. TOVAR JR, Zandonade E, Amorim MHC
    Local recurrence-free survival in women with breast cancer who undergo breast-conserving surgery.
    Breast J. 2019 Jun 6. doi: 10.1111/tbj.13411.
    PubMed     Text format    

  30. SCHREUDER K, Middelburg JG, Aarts MJ, Merkus JWS, et al
    An actualised population-based study on the use of radiotherapy in breast cancer patients in the Netherlands.
    Breast J. 2019 Jun 4. doi: 10.1111/tbj.13376.
    PubMed     Text format     Abstract available

  31. LAFON M, Blaye C, Kind M, Bechade D, et al
    Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1.
    Breast J. 2019 Jun 4. doi: 10.1111/tbj.13386.
    PubMed     Text format     Abstract available

  32. REBOUCAS LM, Campos CS, D'Amico GM, Lustosa AB, et al
    Once-weekly hypofractionated radiotherapy for breast cancer: First results of a phase II clinical trial.
    Breast J. 2019 Jun 4. doi: 10.1111/tbj.13372.
    PubMed     Text format     Abstract available

  33. KHOSRAVI-SHAHI P, Cabezon-Gutierrez L, Aparicio Salcedo MI
    State of art of advanced triple negative breast cancer.
    Breast J. 2019 Jun 2. doi: 10.1111/tbj.13369.
    PubMed     Text format     Abstract available

  34. SADEGHI M, Alamdaran SA, Daneshpajouhnejad P, Layegh P, et al
    A logistic regression nomogram to predict axillary lymph node metastasis in early invasive breast cancer patients.
    Breast J. 2019 Jun 2. doi: 10.1111/tbj.13340.
    PubMed     Text format    

  35. BEN KRIDIS W, Toumi N, Ben Salah H, Sghaier S, et al
    Therapeutic results and prognostic factors of brain metastases from breast cancer: Single center experience.
    Breast J. 2019 Jun 2. doi: 10.1111/tbj.13334.
    PubMed     Text format    

  36. KELEMEN P, Pukancsik D, Ujhelyi M, Kovacs E, et al
    Evaluation of the central pedicled, modified Wise-pattern technique as a standard level II oncoplastic breast-conserving surgery: A retrospective clinicopathological study of 190 breast cancer patients.
    Breast J. 2019 Jun 4. doi: 10.1111/tbj.13371.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  37. LECUYER L, Dalle C, Lyan B, Demidem A, et al
    Plasma metabolomic signatures associated with long-term breast cancer risk in the SU.VI.MAX prospective cohort.
    Cancer Epidemiol Biomarkers Prev. 2019 Jun 4. pii: 1055-9965.EPI-19-0154.
    PubMed     Text format     Abstract available

  38. GUO X, Lin W, Bai M, Li H, et al
    Discovery of a pathogenic variant rs139379666 (p. P2974L) in ATM for breast cancer risk in Chinese populations.
    Cancer Epidemiol Biomarkers Prev. 2019 Jun 3. pii: 1055-9965.EPI-18-1294.
    PubMed     Text format     Abstract available


    Cancer Res

  39. MANSOUR M, Haupt S, Chan AL, Godde N, et al
    Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.
    Cancer Res. 2019;79:3008.
    PubMed     Text format    


    Eur J Cancer

  40. PERRONE F, De Laurentiis M, De Placido S, Orditura M, et al
    Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297.
    PubMed     Text format     Abstract available


    Int J Cancer

  41. AN KY, Morielli AR, Kang DW, Friedenreich CM, et al
    Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32493.
    PubMed     Text format     Abstract available

  42. CYBULSKI C, Kluzniak W, Huzarski T, Wokolorczyk D, et al
    The Spectrum of Mutations Predisposing to Familial Breast Cancer in Poland.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32492.
    PubMed     Text format     Abstract available

  43. WANG S, Pitt JJ, Zheng Y, Yoshimatsu TF, et al
    Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32498.
    PubMed     Text format     Abstract available

  44. GLUZ O, Kolberg-Liedtke C, Prat A, Christgen M, et al
    Efficacy of de-escalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
    Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32488.
    PubMed     Text format     Abstract available


    Int J Oncol

  45. LI P, Liu Y, Liu W, Li G, et al
    IR-783 inhibits breast cancer cell proliferation and migration by inducing mitochondrial fission.
    Int J Oncol. 2019 Jun 6. doi: 10.3892/ijo.2019.4821.
    PubMed     Text format     Abstract available

  46. WANG L, Shi H, Liu Y, Zhang W, et al
    Cystathioninegammalyase promotes the metastasis of breast cancer via the VEGF signaling pathway.
    Int J Oncol. 2019 Jun 6. doi: 10.3892/ijo.2019.4823.
    PubMed     Text format     Abstract available


    J Biol Chem

  47. MCGUIRE CM, Collins MP, Sun-Wada G, Wada Y, et al
    Isoform-specific gene disruptions reveal a role for the V-ATPase subunit a4 isoform in the invasiveness of 4T1-12B breast cancer cells.
    J Biol Chem. 2019 Jun 5. pii: RA119.007713. doi: 10.1074/jbc.RA119.007713.
    PubMed     Text format     Abstract available

  48. STONE JK, Kim JH, Vukadin L, Richard A, et al
    Hypoxia induces cancer cell-specific chromatin interactions and increases MALAT1 expression in breast cancer cells.
    J Biol Chem. 2019 Jun 5. pii: RA118.006889. doi: 10.1074/jbc.RA118.006889.
    PubMed     Text format     Abstract available


    J Clin Invest

  49. KOHRT HE, Houot R, Weiskopf K, Goldstein MJ, et al
    Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
    J Clin Invest. 2019;129:2595.
    PubMed     Text format    


    J Clin Oncol

  50. KANTOR ED, Romano ME
    Phthalate Exposure From Prescription Medications and Breast Cancer Risk.
    J Clin Oncol. 2019 Jun 7:JCO1901003. doi: 10.1200/JCO.19.01003.
    PubMed     Text format    

  51. HURVITZ SA, Martin M, Jung KH, Huang CS, et al
    Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
    J Clin Oncol. 2019 Jun 3:JCO1900882. doi: 10.1200/JCO.19.00882.
    PubMed     Text format     Abstract available

  52. WOLFF AC, Tung NM, Carey LA
    Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 3:JCO1901159. doi: 10.1200/JCO.19.01159.
    PubMed     Text format    

  53. ANDRE F, Ismaila N, Henry NL, Somerfield MR, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
    J Clin Oncol. 2019 May 31:JCO1900945. doi: 10.1200/JCO.19.00945.
    PubMed     Text format     Abstract available

  54. CONFORTI F, Pala L
    Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
    J Clin Oncol. 2019 Jun 7:JCO1900559. doi: 10.1200/JCO.19.00559.
    PubMed     Text format    


    J Natl Cancer Inst

  55. CHOUDHURY PP, Wilcox AN, Brook MN, Zhang Y, et al
    Comparative validation of breast cancer risk prediction models and projections for future risk stratification.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5511406. doi: 10.1093.
    PubMed     Text format     Abstract available

  56. MARIOTTO A, Jayasekerea J, Petkov V, Schechter CB, et al
    Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Apr 24. pii: 5475265. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Surg Oncol

  57. ZHAO B, Tsai C, Hunt KK, Blair SL, et al
    Adherence to surgical and oncologic standards improves survival in breast cancer patients.
    J Surg Oncol. 2019 Jun 6. doi: 10.1002/jso.25506.
    PubMed     Text format     Abstract available


    JAMA

  58. KERLIKOWSKE K, Miglioretti DL, Vachon CM
    Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019.
    JAMA. 2019 May 31. pii: 2735405. doi: 10.1001/jama.2019.6247.
    PubMed     Text format    


    Lancet Oncol

  59. GAIL MH
    Performance of BCRAT in high-risk patients with breast cancer.
    Lancet Oncol. 2019;20:e285.
    PubMed     Text format    

  60. TERRY MB, Liao Y, Hopper JL, MacInnis RJ, et al
    Performance of BCRAT in high-risk patients with breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:e286.
    PubMed     Text format    


    N Engl J Med

  61. IM SA, Lu YS, Bardia A, Harbeck N, et al
    Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
    N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1903765.
    PubMed     Text format     Abstract available

  62. SPARANO JA, Gray RJ, Ravdin PM, Makower DF, et al
    Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2019 Jun 3. doi: 10.1056/NEJMoa1904819.
    PubMed     Text format     Abstract available


  63. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
    N Engl J Med. 2019;380:2282.
    PubMed     Text format    


    Oncogene

  64. GUNARATNA RT, Santos A, Luo L, Nagi C, et al
    Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model.
    Oncogene. 2019;38:3535-3550.
    PubMed     Text format     Abstract available


    Oncol Rep

  65. KAKIZAWA N, Suzuki K, Abe I, Endo Y, et al
    High relative levels of satellite alpha transcripts predict increased risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer and lacking BRCArelated clinical features.
    Oncol Rep. 2019 Jun 3. doi: 10.3892/or.2019.7182.
    PubMed     Text format     Abstract available

  66. MESSEHA SS, Zarmouh NO, Mendonca P, Alwagdani H, et al
    Effects of gossypol on apoptosisrelated gene expression in racially distinct triplenegative breast cancer cells.
    Oncol Rep. 2019 May 31. doi: 10.3892/or.2019.7179.
    PubMed     Text format     Abstract available

  67. YU H, Yang C, Jian L, Guo S, et al
    Sulfasalazineinduced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor.
    Oncol Rep. 2019 Jun 6. doi: 10.3892/or.2019.7189.
    PubMed     Text format     Abstract available


    Oncology

  68. KIM JH, Paik HJ, Jung YJ, Kim DI, et al
    A Prospective Longitudinal Study about Change of Sleep, Anxiety, Depression, and Quality of Life in Each Step of Breast Cancer Patients.
    Oncology. 2019 Jun 4:1-9. doi: 10.1159/000500724.
    PubMed     Text format     Abstract available


    PLoS One

  69. HAJJAR A, Ergun MA, Alagoz O, Rampurwala M, et al
    Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
    PLoS One. 2019;14:e0217778.
    PubMed     Text format     Abstract available


  70. Expression of Concern: Microenvironment Promotes Tumor Cell Reprogramming in Human Breast Cancer Cell Lines.
    PLoS One. 2019;14:e0217961.
    PubMed     Text format    

  71. FULTANG N, Illendula A, Chen B, Wu C, et al
    Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ss activity.
    PLoS One. 2019;14:e0217789.
    PubMed     Text format     Abstract available

  72. ESPLUGAS R, Arenas M, Serra N, Belles M, et al
    Effect of radiotherapy on the expression of cardiovascular disease-related miRNA-146a, -155, -221 and -222 in blood of women with breast cancer.
    PLoS One. 2019;14:e0217443.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  73. MOROTTI M, Bridges E, Valli A, Choudhry H, et al
    Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer.
    Proc Natl Acad Sci U S A. 2019 May 31. pii: 1818521116.
    PubMed     Text format     Abstract available


    Radiology

  74. WERNLI KJ, Ichikawa L, Kerlikowske K, Buist DSM, et al
    Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer.
    Radiology. 2019 Jun 4:182475. doi: 10.1148/radiol.2019182475.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: